Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.65 |
| ▸ | MIF | P14174 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.57 |
| ▸ | DDX3X | O00571 | 5/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312711 | 0.94 | MIF (0.67) | NOTUMMIFCYP19A1DDX3XHSP90AA1 | |
| SCHEMBL17978544 | 0.81 | MIF (0.67) | NOTUMMIFDDX3XKCNH2 | |
| SCHEMBL28014592 | 0.79 | CA12 (0.60) | NOTUMCYP19A1 | |
| SCHEMBL17780718 | 0.79 | NOTUM (0.72) | NOTUMMIFCYP19A1HSP90AA1 | |
| SCHEMBL23451495 | 0.79 | NOTUM (1.00) | NOTUM | |
| SCHEMBL18031109 | 0.77 | MIF (1.00) | MIFCYP19A1DDX3X | |
| SCHEMBL29828549 | 0.76 | MAOA (0.66) | MIFDDX3X | |
| SCHEMBL18031111 | 0.75 | MIF (0.97) | MIFCYP19A1DDX3X | |
| SCHEMBL15923549 | 0.75 | MIF (0.97) | MIFCYP19A1DDX3X | |
| SCHEMBL17978538 | 0.75 | MIF (0.59) | MIFDDX3XKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264769-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | The United States of Americia, as represented by the Secretary, Department of Health and Human Serv (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264769-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | ADORA3, ADORA2A, ADORA1 | NOTUM 4038/4885MIF 1954/4885CYP19A1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.